These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 25313010

  • 1. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A, Katayama R, Oh-Hara T, Sato S, Okuno Y, Fujita N.
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [Abstract] [Full Text] [Related]

  • 2. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q, Zhen Z, Deng DY, Wang J, Chen Y, Li J, Zhang Y, Wang F, Chen N, Chen H, Chen Y.
    J Exp Clin Cancer Res; 2015 Oct 12; 34():118. PubMed ID: 26458953
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
    Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N.
    Cancer Res; 2013 May 15; 73(10):3087-96. PubMed ID: 23598276
    [Abstract] [Full Text] [Related]

  • 4. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.
    Mol Pharmacol; 2019 Jul 15; 96(1):73-89. PubMed ID: 31043459
    [Abstract] [Full Text] [Related]

  • 5. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
    Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P.
    Clin Cancer Res; 2013 May 01; 19(9):2381-92. PubMed ID: 23532890
    [Abstract] [Full Text] [Related]

  • 6. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
    Wang Y, Zhang H, Gigant B, Yu Y, Wu Y, Chen X, Lai Q, Yang Z, Chen Q, Yang J.
    FEBS J; 2016 Jan 01; 283(1):102-11. PubMed ID: 26462166
    [Abstract] [Full Text] [Related]

  • 7. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
    Lindamulage IK, Vu HY, Karthikeyan C, Knockleby J, Lee YF, Trivedi P, Lee H.
    Sci Rep; 2017 Aug 31; 7(1):10298. PubMed ID: 28860494
    [Abstract] [Full Text] [Related]

  • 8. G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly.
    Lv X, He C, Huang C, Hua G, Wang Z, Remmenga SW, Rodabough KJ, Karpf AR, Dong J, Davis JS, Wang C.
    Mol Cancer Ther; 2017 Jun 31; 16(6):1080-1091. PubMed ID: 28258163
    [Abstract] [Full Text] [Related]

  • 9. A novel synthetic microtubule inhibitor, MPT0B214 exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway.
    Chiang NJ, Lin CI, Liou JP, Kuo CC, Chang CY, Chen LT, Chang JY.
    PLoS One; 2013 Jun 31; 8(3):e58953. PubMed ID: 23554962
    [Abstract] [Full Text] [Related]

  • 10. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V.
    Neoplasia; 2015 Mar 31; 17(3):289-300. PubMed ID: 25810013
    [Abstract] [Full Text] [Related]

  • 11. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
    Prota AE, Danel F, Bachmann F, Bargsten K, Buey RM, Pohlmann J, Reinelt S, Lane H, Steinmetz MO.
    J Mol Biol; 2014 Apr 17; 426(8):1848-60. PubMed ID: 24530796
    [Abstract] [Full Text] [Related]

  • 12. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.
    Michieli P, Basilico C, Pennacchietti S.
    Clin Cancer Res; 2013 Aug 01; 19(15):4291. PubMed ID: 23766360
    [No Abstract] [Full Text] [Related]

  • 13. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.
    Rimassa L, Bruix J, Broggini M, Santoro A.
    Clin Cancer Res; 2013 Aug 01; 19(15):4290. PubMed ID: 23766362
    [No Abstract] [Full Text] [Related]

  • 14. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T, Lin S, Ji M, Xue N, Liu Y, Zhang Z, Zhang K, Zhang J, Zhang Y, Wang Q, Sheng L, Li Y, Lu D, Chen X, Xu H.
    Cancer Lett; 2020 Dec 28; 495():22-32. PubMed ID: 32931884
    [Abstract] [Full Text] [Related]

  • 15. SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines.
    Yan W, Yang T, Yang J, Wang T, Yu Y, Wang Y, Chen Q, Bai P, Li D, Ye H, Qiu Q, Zhou Y, Hu Y, Yang S, Wei Y, Li W, Chen L.
    Cell Physiol Biochem; 2018 Dec 28; 47(2):489-504. PubMed ID: 29794416
    [Abstract] [Full Text] [Related]

  • 16. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J, Pang Y, Sheng J, Wang Y, Chen J, Hu J, Huang L, Li X.
    Biochem Pharmacol; 2015 Sep 01; 97(1):51-61. PubMed ID: 26212540
    [Abstract] [Full Text] [Related]

  • 17. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB, Miller DD, Dalton JT.
    Cancer Chemother Pharmacol; 2011 Feb 01; 67(2):293-304. PubMed ID: 20383708
    [Abstract] [Full Text] [Related]

  • 18. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z, Gao M, Zhang H, Guan Q, Xu J, Li Y, Qi H, Li Z, Zuo D, Zhang W, Wu Y.
    Cancer Lett; 2017 Aug 28; 402():81-92. PubMed ID: 28576750
    [Abstract] [Full Text] [Related]

  • 19. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
    Sun K, Sun Z, Zhao F, Shan G, Meng Q.
    Future Med Chem; 2021 May 28; 13(9):839-858. PubMed ID: 33821673
    [Abstract] [Full Text] [Related]

  • 20. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
    Boichuk S, Galembikova A, Syuzov K, Dunaev P, Bikinieva F, Aukhadieva A, Zykova S, Igidov N, Gankova K, Novikova M, Kopnin P.
    Molecules; 2021 Sep 24; 26(19):. PubMed ID: 34641324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.